US Stock MarketDetailed Quotes

MLYS Mineralys Therapeutics

Watchlist
  • 12.950
  • -0.540-4.00%
Trading Dec 3 15:49 ET
644.50MMarket Cap-4204P/E (TTM)

Mineralys Therapeutics Key Stats

Mineralys Therapeutics Q3 2024 Earnings Date

Currency:USDNov 11, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
0
0
0
--
--
--
EPS
-0.82
-1.13
-0.31
Miss Est.
-44.74%
-98.25%
-36.99%
Strong Buy

Nov 30, 2024

Mineralys Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 11, 20242024/Q30.000 / 0.000--
Aug 13, 20242024/Q20.000 / 0.000--
May 9, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 11, 20242024/Q30.000 / 0.000--
Aug 13, 20242024/Q20.000 / 0.000--
May 9, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Mineralys Therapeutics Earnings Reports

Read more

Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Nov 30, 2024

Strong Buy

  • Buy

    100.00%
  • Hold

    0.00%
  • Sell

    0.00%

Price Target

No Data